ArticleCureus2025
Functional Outcomes of Anatomic Total Shoulder Arthroplasty in Patients Over 60 Years Old: A Retrospective Study (2019-2024).
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Anatomic shoulder arthroplasty: a single surgeon's consecutive series of four hundred and fifty eight patients.International orthopaedics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background This study aimed to evaluate the functional outcomes, complications, and revision rates of anatomic total shoulder arthroplasty (aTSA) in patients over 60 years old with intact rotator cuffs. Methodology A retrospective analysis was conducted among 42 (100%) patients aged over 60 who underwent aTSA between 2019 and 2024 in two hospitals. Patients were included if they had severe shoulder arthritis and an intact rotator cuff. All procedures utilised a standardised deltopectoral approach with implantation of a stemmed uncemented humeral component and a keeled cemented polyethylene glenoid (Tornier Perform Anatomic Glenoid, Stryker Corporation, Kalamazoo, MI, USA), with a minimum follow-up of 12 months postoperatively. Demographic data were collected along with pre- and postoperative Oxford Shoulder Score (OSS) and American Shoulder and Elbow Surgeons (ASES) scores, glenoid morphology (assessed via the Walch classification), and complications. Statistical analysis was performed using paired t-tests to compare pre- and postoperative scores. Results The study included 42 (100%) patients; 35 (83%) females and 7 (16.7%) males with a mean age of 74.5 years. The mean duration of follow-up was 30 months. The mean preoperative OSS was 18.3 (SD = 9.7), which significantly improved to 46 postoperatively (SD = 3.1, range = 38-48, p < 0.0001). Overall, 40 (95.23%) patients achieved a postoperative OSS over 40, with 20 (47.62%) patients scoring the maximum of 48. The ASES score averaged 93, with 33 (78.57%) patients scoring between 80 and 100. Glenoid morphology analysis revealed A2 as the most common type observed in 18 (42.86%) patients. Complications were minimal, with occasional pain reported in four (9.52%) patients, while no patients returned to theatre. Conclusions aTSA demonstrates significant improvements in shoulder function and pain relief for elderly patients with intact rotator cuffs. The high postoperative OSS and ASES scores, along with low complication rates, support the effectiveness of aTSA in this population. These findings suggest that it is a viable and successful surgical option for elderly patients with glenohumeral osteoarthritis, even in those over 70 years old, challenging the growing trend toward reverse total shoulder arthroplasty in this age group. Further research is needed to explore long-term outcomes and refine surgical indications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.